TScan Therapeutics, Inc. Common Stock (TCRX) is a publicly traded Healthcare sector company. As of August 12, 2026, TCRX trades at $0.78 with a market cap of $50.12M and a P/E ratio of -0.80. TCRX moved +0.28% today. Year to date, TCRX is -22.32%; over the trailing twelve months it is -51.75%. Its 52-week range spans $0.72 to $3.43. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces TCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
5 analysts cover TCRX: 0 strong buy, 4 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $6.00.
| Metric | Value |
|---|---|
| Price | $0.78 |
| Market Cap | $50.12M |
| P/E Ratio | -0.80 |
| EPS | $-0.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.43 |
| 52-Week Low | $0.72 |
| Volume | 2.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $9.14M |
| Net Income | $-124.31M |
| Gross Margin | 0.00% |
5 analysts cover TCRX: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.